Literature DB >> 23881609

Impact of a drug utilization review program on high-risk use of prescription controlled substances.

Matthew Daubresse1, Patrick P Gleason, Yi Peng, Nilay D Shah, Stephen T Ritter, G Caleb Alexander.   

Abstract

BACKGROUND: Prescription drug abuse has prompted considerable concern. We evaluated a retrospective drug utilization review program to reduce controlled substance use among individuals with high-risk utilization.
METHODS: We analyzed pharmacy claims from a large pharmaceutical benefits manager. For each eligible member, we calculated a controlled substance score based on the number and type of claims, prescribers and pharmacies, and utilization patterns over three months. Two state health plans sent controlled substance letters to prescribers of members meeting or exceeding a plan- and pre-specified controlled substance score. Two different state health plans did not send such letters. We used a difference-in-difference design and generalized estimating equations to quantify the impact of the program on the mean difference in reduction of the controlled substance score over six months.
RESULTS: Eligible members in the intervention and comparison states had similar baseline mean controlled substance scores (19.0 vs. 18.6, p = 0.36). Adjusting for individuals' age, sex and pharmacy risk group score, reductions in the mean controlled substance score were greater in the intervention than comparison cohort (5.67 vs. 4.31, p = 0.01), corresponding with a 34.0% reduction in the intervention cohort compared to a 25.5% reduction in the comparison cohort. Changes were driven primarily by reductions in the number of controlled substance claims filled (30.5% vs. 23.1%, p = 0.01), as well as by a non-statistically significant trend towards reductions in the number of prescribers and pharmacies used (26.9% vs. 20.1%, p = 0.07).
CONCLUSIONS: Retrospective drug utilization review programs may reduce controlled substance scores and claims among individuals with patterns suggesting high-risk utilization.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  drug utilization review; pharmacoepidemiology; pharmacy benefits manager; prescription opioids

Mesh:

Substances:

Year:  2013        PMID: 23881609     DOI: 10.1002/pds.3487

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  7 in total

Review 1.  What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose.

Authors:  Tamara M Haegerich; Leonard J Paulozzi; Brian J Manns; Christopher M Jones
Journal:  Drug Alcohol Depend       Date:  2014-10-14       Impact factor: 4.492

2.  Trends in Opioid Prescribing Among Hemodialysis Patients, 2007-2014.

Authors:  Matthew Daubresse; G Caleb Alexander; Deidra C Crews; Dorry L Segev; Mara A McAdams-DeMarco
Journal:  Am J Nephrol       Date:  2018-12-13       Impact factor: 3.754

3.  Screening, Brief Intervention, and Referral to Treatment in a Retail Pharmacy Setting: The Pharmacist's Role in Identifying and Addressing Risk of Substance Use Disorder.

Authors:  Brian C Shonesy; Donald Williams; Damian Simmons; Erin Dorval; Stuart Gitlow; Richard M Gustin
Journal:  J Addict Med       Date:  2019 Sep/Oct       Impact factor: 3.702

4.  Association of opioid utilization management with prescribing and overdose.

Authors:  Martin S Andersen; Vincent Lorenz; Anurag Pant; Jeremy W Bray; G Caleb Alexander
Journal:  Am J Manag Care       Date:  2022-02-01       Impact factor: 2.229

5.  A Rapid Review of the Impact of Systems-Level Policies and Interventions on Population-Level Outcomes Related to the Opioid Epidemic, United States and Canada, 2014-2018.

Authors:  Bahareh Ansari; Katherine M Tote; Eli S Rosenberg; Erika G Martin
Journal:  Public Health Rep       Date:  2020 Jul/Aug       Impact factor: 2.792

6.  The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.

Authors:  P M Coplan; H D Chilcoat; S F Butler; E M Sellers; A Kadakia; V Harikrishnan; J D Haddox; R C Dart
Journal:  Clin Pharmacol Ther       Date:  2016-06-22       Impact factor: 6.875

7.  Evidence for state, community and systems-level prevention strategies to address the opioid crisis.

Authors:  Tamara M Haegerich; Christopher M Jones; Pierre-Olivier Cote; Amber Robinson; Lindsey Ross
Journal:  Drug Alcohol Depend       Date:  2019-09-19       Impact factor: 4.852

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.